Short-acting analogues (Lispro and Aspart) have faster onset and shorter duration of action determining a more overlapping peak to the one of the endogenous insulin, reducing the risk of post-meal hypoglycemia and improving glycemic control in women with GDM (4, 5). The gene discussed is INS; the disease is gestational diabetes.